Verastem Oncology
117 Kendrick Street
Suite 500
Needham
MA
02494
United States
Tel: (718) 292-4200
Website: http://www.verastem.com/
Email: info@verastem.com
About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) is a clinical-stage biopharmaceutical company committed to the development and commercialization of medicines to improve the lives of patients diagnosed with cancer. We are driven by the strength, tenacity and courage of those battling cancer – single-minded in our resolve to deliver new therapies that not only keep cancer at bay, but improve the lives of patients diagnosed with cancer. Because for us, it’s personal.
Our team is anchored by core values of character, urgency, respect and excellence. We pride ourselves in being an organization committed to diversity and inclusion in order to achieve and sustain excellence. At Verastem, we believe that empowering employees is what makes them truly care about the important work they do.
Founded: 2010
307 articles with Verastem Oncology
-
Verastem Oncology to Announce Third Quarter 2019 Financial Results and Corporate Update on October 29, 2019
10/17/2019
Verastem, Inc. announced that the Company will host a conference call and webcast on Tuesday, October 29, 2019 at 4:30 p.m.
-
Verastem Oncology Announces Dosing of First Patient in Yakult Honsha Co., Ltd.’s Japanese Bridging Study Evaluating COPIKTRA® (Duvelisib) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
10/7/2019
Verastem, Inc., announced that its partner Yakult Honsha Co., Ltd. has dosed the first patient in a Phase 1b Japanese bridging study evaluating COPIKTRA® in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma following at least one prior therapy.
-
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct. 4, 2019
10/4/2019
Verastem, Inc., a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, announced the grant of options to purchase 126,363 shares of its common stock to ten new employees.
-
Verastem Oncology Receives Orphan Drug Designation from FDA for COPIKTRA for the Treatment of T-Cell Lymphoma
10/3/2019
Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced duvelisib (COPIKTRATM) has received orphan drug designation from the U.S. Food and Drug Administration for use in the treatment of T-Cell lymphoma.
-
Verastem Oncology Presents New Preclinical Duvelisib Data at the 5th International Conference on New Concepts in Lymphoid Malignancies
10/3/2019
Duvelisib’s Dual Inhibition of PI3K-Delta and PI3K-Gamma Inhibits Migration and Proliferation of Mantle Cell Lymphoma Cells More Effectively Than PI3K-Delta Alone in Preclinical Models
-
Verastem Oncology to Present at the Cantor 2019 Global Healthcare Conference
9/26/2019
Verastem, Inc. announced that the Company will present at the Cantor 2019 Global Healthcare Conference on Thursday, October 3, 2019 at 8:20 a.m. EDT in New York, NY.
-
Verastem Oncology Announces COPIKTRA™ (Duvelisib) Presentations at the 18th Annual International Workshop on Chronic Lymphocytic Leukemia
9/20/2019
Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced that three posters highlighting clinical data for COPIKTRA™ (duvelisib) will be presented at the 18th Annual International Workshop on Chronic Lymphocytic Leukemia taking place September 20-23, 2019, in Edinburgh, UK.
-
Verastem Oncology Announces COPIKTRA™ (Duvelisib) Presentations at the Society of Hematologic Oncology 2019 Annual Meeting
9/3/2019
Verastem, Inc. announced that four posters highlighting clinical data for COPIKTRA™ will be presented at the Society of Hematologic Oncology 2019 Annual Meeting taking place September 11-14, 2019, in Houston.
-
Verastem Oncology to Present at the 21st Annual H.C. Wainwright Global Investment Conference
9/3/2019
Verastem, Inc. (Nasdaq: VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced that the Company will present at the 21st Annual H.C. Wainwright Global Investment Conference on Tuesday,
-
Verastem Oncology Reports Second Quarter 2019 Financial Results and Highlights Recent Company Progress
8/1/2019
Verastem, Inc. (Nasdaq: VSTM), operating as Verastem Oncology (or “the Company”), focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today reported financial results for the three months ended June 30, 2019, and provided an overview of recent accomplishments and clinical development progress for duvelisib (COPIKTRA®).
-
Verastem Oncology Appoints Brian Stuglik as Chief Executive Officer
7/29/2019
Verastem, Inc. (Nasdaq: VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced that Brian Stuglik, a member of the Board of Directors, has been named Chief Executive Officer (CEO).
-
Verastem Oncology to Announce Second Quarter 2019 Financial Results and Corporate Update on August 1, 2019
7/25/2019
Verastem, Inc. announced that the Company will host a conference call and webcast on Thursday, August 1, 2019 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the second quarter ended June 30, 2019.
-
Verastem Oncology Signs an Exclusive License Agreement with Sanofi for the Development and Commercialization of COPIKTRA® (duvelisib) in Russia and CIS, Turkey, the Middle East and Africa
7/25/2019
Verastem, Inc. (NASDAQ: VSTM) operating as Verastem Oncology, (or “the Company”), today announced their entry into an exclusive licensing agreement with Sanofi to develop and commercialize Verastem Oncology’s COPIKTRA® (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K), and the first approved dual inhibitor of PI3K-delta and PI3K-gamma, for the treatment of all oncology indications in Russia and CIS, Turkey, the Middle East and Africa.
-
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 3, 2019
7/3/2019
Verastem, Inc., a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, announced the grant of options to purchase 104,000 shares of its common stock to five new employees.
-
Verastem Oncology Presents COPIKTRA™ (Duvelisib) Data in Peripheral T-Cell Lymphoma at the 2019 International Conference on Malignant Lymphoma
6/21/2019
Verastem, Inc. announced an oral presentation highlighting supportive Phase 1 clinical data for duvelisib in patients with relapsed or refractory peripheral T-cell lymphoma at the 2019 International Conference on Malignant Lymphoma being held June 18-22, 2019, in Lugano, Switzerland.
-
BioSpace Movers and Shakers, June 21
6/21/2019
Biotech and pharma companies strengthen their leadership teams and committees with new appointments. -
Verastem Oncology Announces Leadership Changes
6/20/2019
Verastem, Inc., a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced that Robert Forrester has decided to step down as President and Chief Executive Officer. Mr. Forrester has agreed to continue serving Verastem Oncology in an advisory capacity.
-
Chief Operating Officer Dan Paterson has been appointed to the role of president and will lead the company while the board of directors conducts a search for a new CEO.
-
Verastem Oncology Presents COPIKTRA™ (Duvelisib) Data at the European Hematology Association 2019 Annual Meeting
6/17/2019
In CLL/SLL Patients in the DUO Study, Duvelisib Treatment Rapidly Increased Lymphocytes and Resulted in Shrinkage of Lymph Nodes, With 86% of Patients Achieving a Lymph Node Response
-
Verastem Oncology to Present at the Jefferies 2019 Global Healthcare Conference
5/30/2019
Verastem, Inc. announced that the Company will present at the Jefferies 2019 Global Healthcare Conference on Friday, June 7, 2019 at 11:30 a.m. EDT in New York, NY.